449 related articles for article (PubMed ID: 21147825)
21. The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy.
Hachem R; Hanna H; Kontoyiannis D; Jiang Y; Raad I
Cancer; 2008 Jun; 112(11):2493-9. PubMed ID: 18412153
[TBL] [Abstract][Full Text] [Related]
22. Activities of flucytosine, fluconazole, amphotericin B, and micafungin in a murine model of disseminated infection by Candida glabrata.
Mariné M; Serena C; Fernández-Torres B; Pastor FJ; Guarro J
Antimicrob Agents Chemother; 2005 Nov; 49(11):4757-9. PubMed ID: 16251323
[TBL] [Abstract][Full Text] [Related]
23. A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients.
de Wet N; Llanos-Cuentas A; Suleiman J; Baraldi E; Krantz EF; Della Negra M; Diekmann-Berndt H
Clin Infect Dis; 2004 Sep; 39(6):842-9. PubMed ID: 15472817
[TBL] [Abstract][Full Text] [Related]
24. Candida glabrata fungaemia in a tertiary centre in Taiwan: antifungal susceptibility and outcomes.
Ruan SY; Huang YT; Chu CC; Yu CJ; Hsueh PR
Int J Antimicrob Agents; 2009 Sep; 34(3):236-9. PubMed ID: 19361960
[TBL] [Abstract][Full Text] [Related]
25. Failure of echinocandin therapy in the treatment of Candida glabrata chorioretinitis.
Mousselli HA; Norwood J
Am J Med Sci; 2012 Jan; 343(1):98-100. PubMed ID: 22052412
[TBL] [Abstract][Full Text] [Related]
26. Micafungin: a review of its use in adults for the treatment of invasive and oesophageal candidiasis, and as prophylaxis against Candida infections.
Cross SA; Scott LJ
Drugs; 2008; 68(15):2225-55. PubMed ID: 18840009
[TBL] [Abstract][Full Text] [Related]
27. Therapy and outcome of Candida glabrata versus Candida albicans bloodstream infection.
Klevay MJ; Ernst EJ; Hollanbaugh JL; Miller JG; Pfaller MA; Diekema DJ
Diagn Microbiol Infect Dis; 2008 Mar; 60(3):273-7. PubMed ID: 18024053
[TBL] [Abstract][Full Text] [Related]
28. Micafungin: A Review in the Prophylaxis and Treatment of Invasive Candida Infections in Paediatric Patients.
Scott LJ
Paediatr Drugs; 2017 Feb; 19(1):81-90. PubMed ID: 28083856
[TBL] [Abstract][Full Text] [Related]
29. Caspofungin use in patients with invasive candidiasis caused by common non-albicans Candida species: review of the caspofungin database.
Colombo AL; Ngai AL; Bourque M; Bradshaw SK; Strohmaier KM; Taylor AF; Lupinacci RJ; Kartsonis NA
Antimicrob Agents Chemother; 2010 May; 54(5):1864-71. PubMed ID: 20231388
[TBL] [Abstract][Full Text] [Related]
30. Candida krusei fungaemia: antifungal susceptibility and clinical presentation of an uncommon entity during 15 years in a single general hospital.
Muñoz P; Sánchez-Somolinos M; Alcalá L; Rodríguez-Créixems M; Peláez T; Bouza E
J Antimicrob Chemother; 2005 Feb; 55(2):188-93. PubMed ID: 15650001
[TBL] [Abstract][Full Text] [Related]
31. Economic evaluation of micafungin vs. liposomal amphotericin B (LAmB) for the treatment of candidaemia and invasive candidiasis (IC).
Neoh CF; Liew D; Slavin MA; Marriott D; Chen SC; Morrissey O; Stewart K; Kong DC
Mycoses; 2013 Sep; 56(5):532-42. PubMed ID: 23496163
[TBL] [Abstract][Full Text] [Related]
32. A retrospective Evaluation of fluconazole for the treatment of Candida glabrata fungemia.
Wilson AG; Micek ST; Ritchie DJ
Clin Ther; 2005 Aug; 27(8):1228-37. PubMed ID: 16199247
[TBL] [Abstract][Full Text] [Related]
33. Comparative effects of micafungin, caspofungin, and anidulafungin against a difficult-to-treat fungal opportunistic pathogen, Candida glabrata.
Spreghini E; Orlando F; Sanguinetti M; Posteraro B; Giannini D; Manso E; Barchiesi F
Antimicrob Agents Chemother; 2012 Mar; 56(3):1215-22. PubMed ID: 22203604
[TBL] [Abstract][Full Text] [Related]
34. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry.
Horn DL; Neofytos D; Anaissie EJ; Fishman JA; Steinbach WJ; Olyaei AJ; Marr KA; Pfaller MA; Chang CH; Webster KM
Clin Infect Dis; 2009 Jun; 48(12):1695-703. PubMed ID: 19441981
[TBL] [Abstract][Full Text] [Related]
35. Breakthrough invasive candidiasis in patients on micafungin.
Pfeiffer CD; Garcia-Effron G; Zaas AK; Perfect JR; Perlin DS; Alexander BD
J Clin Microbiol; 2010 Jul; 48(7):2373-80. PubMed ID: 20421445
[TBL] [Abstract][Full Text] [Related]
36. Candidaemia in adult cancer patients: risks for fluconazole-resistant isolates and death.
Slavin MA; Sorrell TC; Marriott D; Thursky KA; Nguyen Q; Ellis DH; Morrissey CO; Chen SC;
J Antimicrob Chemother; 2010 May; 65(5):1042-51. PubMed ID: 20202987
[TBL] [Abstract][Full Text] [Related]
37. [Activity of micafungin against Candida biofilms].
Quindós G; Villar-Vidal M; Eraso E
Rev Iberoam Micol; 2009 Mar; 26(1):49-55. PubMed ID: 19463277
[TBL] [Abstract][Full Text] [Related]
38. Micafungin treatment and eradication of candiduria among hospitalized patients.
Gabardi S; Martin S; Sura M; Mohammed A; Golan Y
Int Urol Nephrol; 2016 Nov; 48(11):1881-1885. PubMed ID: 27587066
[TBL] [Abstract][Full Text] [Related]
39. Economic evaluation of micafungin versus caspofungin for the treatment of candidaemia and invasive candidiasis.
Neoh CF; Liew D; Slavin MA; Marriott D; Chen SC; Morrissey O; Stewart K; Kong DC
Intern Med J; 2013 Jun; 43(6):668-77. PubMed ID: 23461421
[TBL] [Abstract][Full Text] [Related]
40. Empirical Micafungin Treatment and Survival Without Invasive Fungal Infection in Adults With ICU-Acquired Sepsis, Candida Colonization, and Multiple Organ Failure: The EMPIRICUS Randomized Clinical Trial.
Timsit JF; Azoulay E; Schwebel C; Charles PE; Cornet M; Souweine B; Klouche K; Jaber S; Trouillet JL; Bruneel F; Argaud L; Cousson J; Meziani F; Gruson D; Paris A; Darmon M; Garrouste-Orgeas M; Navellou JC; Foucrier A; Allaouchiche B; Das V; Gangneux JP; Ruckly S; Maubon D; Jullien V; Wolff M;
JAMA; 2016 Oct; 316(15):1555-1564. PubMed ID: 27706483
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
